From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along for much of the journey and has experienced setbacks, but also huge discoveries. “It’s amazing when you succeed,” she says.
While Novo Nordisk makes headlines for its exceptional expansion in obesity and diabetes, another Danish pharmaceutical company is pushing ahead and growing rapidly in antibodies.
Since its inception in 1999, Genmab has grown from 10 to over 2,100 employees, and the company’s antibody technology forms the basis of eight approved therapies.
News in English
